NEW Financial Headlines Page and Summary Report
We are launching a new Financial Headlines webpage and summary report available on request to stakeholders. The RDTC produces 3 financial headlines reports – Monthly Financial Headlines, Top 50 BNF sections and drugs, Price Concessionary Bulletin – with a wide range and comprehensive set of financial data for users to interrogate, and we thought it might be useful to provide a report which summarises the headline information from within each of these in a short, compact, easy to read format.
This report is available on request summarising the North of England ICBs financial position or the data for each of the SICBLs within your ICB. A free version available for download summarising the national regional position can be found on our new Financial Headlines webpage for download. On this page we will keep you informed of any new updates to our reports, links to any other relevant RDTC publications and any relevant financial headline news.
If you would like a copy of the new financial headlines summary report or have any comments, queries and feedback, please contact us at nuth.nyrdtc.rxsupp@nhs.net.
Formulary amendments August 2026 & horizon scanning September 2026
wo new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:
- Monthly formulary amendments – August 2026
- Monthly horizon scanning – September 2026
Formulary amendments July 2026 & horizon scanning August 2026
wo new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:
- Monthly formulary amendments – July 2026
- Monthly horizon scanning – August 2026
Formulary amendments June 2026 & horizon scanning July 2026
wo new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:
- Monthly formulary amendments – June 2026
- Monthly horizon scanning – July 2026
Formulary amendments May 2026 & horizon scanning June 2026
wo new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:
- Monthly formulary amendments – May 2026
- Monthly horizon scanning – June 2026
Formulary amendments April 2026 & horizon scanning May 2026
Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in April 2026:
- Monthly formulary amendments – April 2026
- Monthly horizon scanning – May 2026
Formulary amendments March 2026 & horizon scanning April 2026
Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in March 2026:
- Monthly formulary amendments – March 2026
- Monthly horizon scanning – April 2026
Formulary assessment – levodopa inhalation powder (Inbrija)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
The Formulary Assessment tool for inhaled levodopa can be accessed here
Formulary amendments February 2026 & horizon scanning March 2026
Two new monthly publications are now available for stakeholders, covering new and updated medicines, guidelines, and safety alerts published in February 2026:
- Monthly formulary amendments – February 2026
- Monthly horizon scanning – March 2026
Switching from disposable to reusable insulin pens
This document outlines the benefits of appropriate switching from disposable to reusable insulin pens, highlighting advantages for patients, the environment, and potential cost savings. It also provides practical recommendations for implementation by medicines optimisation teams
The switching from disposable to reusable insulin pens bulletin can be accessed here